-+ 0.00%
-+ 0.00%
-+ 0.00%

Nykode Therapeutics Wins New US Patent for Neoantigen-based Cancer Vaccine

MT Newswires·08/20/2026 10:52:27
Listen to the news
10:52 AM EDT, 08/20/2026 (MT Newswires) -- Biopharmaceutical company Nykode Therapeutics (NYKD.OL) said Thursday it secured a new US patent related to its fully individualized neoantigen-based cancer vaccine candidate, VB10.NEO. The patent from the US Patent and Trademark Office also covers similar modular neoantigen-based cancer vaccines that use alternative targeting units and/or dimerization units. It remains valid for 20 years, through Jan. 5, 2037.